COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI HC QHC Q BHBH CICI BLBL NZNZ COCO BUBU More..
Home  
Share  
Tweet
00.250.50.7511.251.51.752+Ruzhentsova (RCT)0.94[0.78-1.14]hosp.3/1122/56RRCITreatmentControlUdwadia (RCT)0.60[0.35-1.02]recov. time7575Dabbous (RCT)0.55[0.05-5.81]death1/442/48Tau​2 = 0.00; I​2 = 0.0%Early treatment0.62[0.38-1.02]4/2314/17938% improvementCai0.31[0.10-0.96]pneumonia3545RRCITreatmentControlIvashchenko (RCT)0.54[0.33-0.88]viral+15/4014/20Pushkar (RCT)0.86[0.74-0.99]no recov.73/10085/100Solaymani-.. (RCT)1.20[0.70-2.06]death26/19321/187OT​1Tau​2 = 0.07; I​2 = 57.9%Late treatment0.77[0.53-1.11]114/368120/35223% improvementAll studies0.76[0.59-0.98]118/599124/53124% improvement7 favipiravir COVID-19 studiesc19favipiravir.com 4/18/211 OT: comparison with other treatmentTau​2 = 0.03; I​2 = 31.0%; Z = 2.14 (p = 0.016)Lower RiskIncreased Risk
 
Search:  
Restrict:    All    Early    Late
4/17
Early Fujii et al., Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2021.04.013 (Peer Reviewed) Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients
Retrospective 41 favipiravir patients noting that early treatment is more successful.
3/11
Late Solaymani-Dodaran et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.107522 (Peer Reviewed) death, ↑19.2%, p=0.54 Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
RCT late stage patients (median SpO2 89), 193 treated with favipiravir, 187 with lopinavir/ritonavir, showing no significant differences in mortality, intubation, or ICU admission.
3/8
Late Fateh et al., medRxiv, doi:10.1101/2021.03.05.21251351 (Preprint) A single-center retrospective cohort study of Covid-19 medications: Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations
Retrospective 324 hospitalized patients in Iran reporting on the use Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations. There is no control group in this study.
2/4
Early, Late Uçan et al., Research Square, doi:10.21203/rs.3.rs-175340/v1 (Preprint) Benefits of Treatment With Favipiravir in Hospitalized Patients for COVID-19: a Retrospective Observational Case-control Study
Retrospective 144 COVID-19 patients in Turkey, one group receiving FPV after a mean of 4.7 days, a second group after a mean of 8.6 days, and all groups receiving HCQ. No improvement in clinical outcomes was seen with the addition of FPV,..
1/25
Early Dabbous et al., Archives of Virology, doi:10.1007/s00705-021-04956-9 (Peer Reviewed) death, ↓45.5%, p=0.12 Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
RCT with 44 favipiravir patients and 48 CQ patients, showing non-statistically significant lower mortality, ventilation, and hospitalization time with favipiravir.
1/14
Early Karatas et al., Research Square, doi:10.21203/rs.3.rs-142868/v1 (Preprint) Early Onset Favipiravir Saves Lives
Retrospective 180 hospitalized patients showing lower mortality when Favipiravir is given earlier. 17% of patients given Favipiravir within 3 days died, compared to 38% when given after 3 days.
11/16
Early Udwadia et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.142 (Peer Reviewed) recov. time, ↓40.0%, p=0.03 Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial
RCT with 75 favipiravir patients and 75 control patients showing reduced time to clinical cure and reduced time of viral shedding.
11/9
Late Khamis et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.008 (Peer Reviewed) Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia
Small 89 patient RCT comparing favipiravir and inhaled interferon with HCQ for moderate to severe COVID-19 pneumonia, not finding significant differences. There was no control group.
11/5
Late Pushkar et al., NCT04542694 (Preprint) no recov., ↓14.1%, p=0.06 Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
RCT 200 patients showing improvements in clinical recovery and viral clearance with favipiravir. There is no paper available but results are posted in clinicaltrials.gov.
10/26
Early Ruzhentsova et al., SSRN, doi:10.2139/ssrn.3696907 (Preprint) hosp., ↓6.0%, p=0.49 Phase 3 Trial of Coronavir (Favipiravir) in Patients with Mild to Moderate COVID-19
RCT 168 patients, 112 receiving favipiravir and 56 SOC, showing shorter time to clinical improvement and faster viral clearance with favipiravir.
8/9
Late Ivashchenko et al., Clin. Infect. Dis., doi:10.1093/cid/ciaa1176 (Peer Reviewed) viral+, ↓46.4%, p=0.03 AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
Intermin results for a small RCT with 40 favipiravir and 20 control patients showing faster viral clearance with favipiravir. There is limited data in this report to evaluate the results. The report indicates that 75% of the control group..
3/18
Late Cai et al., Engineering, doi:10.1016/j.eng.2020.03.007 (Peer Reviewed) pneumonia, ↓68.7%, p=0.04 Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Comparison of 35 FPV patients and 35 LPV/RTV patients, showing significant improvements in chest CT and faster viral clearance with FPV.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation.
Submit